SV2A PET is a promising research biomarker for biological characterization of synucleinopathies, however, the field remains limited by small cohorts, methodological heterogeneity, variable quantification strategies, limited longitudinal evidence, and potential cohort overlap.
Abstract Background Over four decades of research have linked synaptic pathology to a broad range of brain disorders. Postmortem studies in conditions like psychosis spectrum disorders, Parkinson’s and Alzheimer’s Disease (AD) show changes in synaptic integrity but are confounded by factors such as illness duration or...
G. Mirfallah, C. Schifani, D. Shateri et al.· International Journal of Neu...· 0 citations
Synaptic loss is a core pathological feature of neurodegenerative disorders and closely relates to cognitive and functional decline. Positron emission tomography (PET) targeting synaptic vesicle glycoprotein 2A (SV2A) has recently emerged as a promising tool for the indirect assessment of presynaptic alterations in the...
L. Filippi, S. Nuvoli, A. Spanu et al.· Molecular Diagnosis & Therap...· 0 citations
The biomarker and therapeutic potential of STX1A remains preliminary because diagnostic performance, disease specificity, longitudinal stability, and causal relevance have not been adequately validated and future studies using cell-type-specific STX1A manipulation, rescue experiments, electrophysiology, and multicenter...
Rui Xu, Rui Li, Hong-Mei Li et al.· Frontiers in Aging Neuroscie...· 0 citations
Current evidence supports neuroinflammation imaging primarily for mechanistic investigation, patient stratification, and trial enrichment rather than routine clinical deployment, and should therefore be interpreted as a collection of target-specific, stage-dependent biological readouts rather than as a unitary measure...
This review summarizes motor system degeneration in aging and disease, focusing on the primary motor cortex (M1), its white matter tracts, and the nigrostriatal system.
OBJECTIVE
Scans Without Evidence of Dopaminergic Deficit (SWEDD) refers to individuals with Parkinsonian symptoms but no presynaptic dopaminergic deficit on dopamine transporter (DAT) imaging. Given its likely heterogeneity, we used a multimodal imaging approach to compare SWEDD with Parkinson's disease (PD) and health...
Faranak Ebrahimian Sadabad, Tommaso Volpi, Sule Tinaz et al.· Parkinsonism & Related Disor...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
